COO

Rosen Law Firm is investigating potential securities claims against The Cooper Companies, Inc. (NASDAQ: COO) for allegedly issuing materially misleading business information. The investigation was prompted by Cooper Companies' disappointing earnings report on September 10, 2026, which included weak guidance and a decision not to sell Cooper Surgical, causing the stock to fall 14.6% that day. Investors who purchased Cooper Companies securities may be eligible for compensation through a class action lawsuit.

Rosen Law Firm has launched an investigation into potential securities claims against The Cooper Companies, Inc. (NASDAQ: COO) following allegations of materially misleading business information. The investigation was prompted by Cooper Companies' September 10, 2026 earnings report that disappointed Wall Street with weak guidance and a decision not to sell Cooper Surgical, resulting in a 14.6% stock decline. The firm is preparing a class action lawsuit to recover investor losses on a contingency fee basis.

Rosen Law Firm is investigating potential securities claims against The Cooper Companies, Inc. (NASDAQ: COO) for allegedly issuing materially misleading business information. The investigation was prompted by Cooper Companies' disappointing earnings report on September 10, 2026, which included weak guidance and a decision not to sell Cooper Surgical, causing the stock to fall 14.6% that day. Investors who purchased Cooper Companies securities may be eligible for compensation through a class action lawsuit.

The Cooper Companies reported Q3 fiscal 2026 adjusted EPS of $1.15, beating estimates by 3.6%, but revenues of $1.066 billion missed consensus by 3.0%. The CooperVision segment faced pressure from U.S. channel inventory reductions, while CooperSurgical showed steady growth. Downward estimate revisions and a Zacks Rank #5 (Strong Sell) rating reflect investor concerns about near-term performance.

Rosen Law Firm is investigating potential securities claims against The Cooper Companies, Inc. (NASDAQ: COO) for allegedly issuing materially misleading business information. The investigation was prompted by Cooper Companies' September 10, 2026 earnings report that disappointed Wall Street with weak guidance and a decision not to sell Cooper Surgical, causing the stock to fall 14.6% that day. Investors who purchased Cooper Companies securities may be eligible for compensation through a class action lawsuit.

The Cooper Companies faces a securities fraud investigation following disappointing Q3 2026 results. The company reported flat year-over-year revenue of $717 million, attributed to U.S. channel inventory reductions. Cooper lowered full-year guidance by approximately 1.4% in revenue and 1.8% in EPS, causing shares to decline 14.67% on September 10, 2026.

Rosen Law Firm has announced an investigation into potential securities claims against The Cooper Companies, Inc. (NASDAQ: COO) for allegedly issuing materially misleading business information. The investigation was triggered by CooperCompanies' disappointing earnings report on September 10, 2026, which included weak guidance and a decision not to sell CooperSurgical, causing the stock to fall 14.6%. Investors who purchased CooperCompanies securities may be eligible for compensation through a class action lawsuit.

The Rosen Law Firm is investigating potential securities claims against The Cooper Companies, Inc. following a 14.6% stock decline on September 10, 2026, after disappointing earnings guidance and a decision not to sell Cooper Surgical. Investors who purchased Cooper Companies securities may be eligible for compensation through a class action lawsuit.

Rosen Law Firm has announced an investigation into potential breaches of fiduciary duties by directors and officers of Sprout Social, Inc. The firm is encouraging current shareholders to contact them regarding their rights. Rosen Law Firm is also investigating securities claims for The Cooper Companies, Inc. and has filed a class action lawsuit for Netcapital Inc. investors.

Cooper Companies director Paul Keel purchased 4,701 shares worth $250,000 at $53.18 per share on September 11, 2026, following a 21% year-long stock decline. The insider buy is viewed as a bullish signal, suggesting confidence in the company's long-term growth prospects. Keel, who recently joined Cooper's board in May, brings extensive experience from his CEO role at Envista Holdings and prior positions at 3M.

Lawrence Erik Kurzius, a Director at Cooper Companies, purchased 10,000 shares worth $549,300 at $54.93 per share on September 16, 2026, increasing his total holdings to 31,099 shares. The insider buy signals confidence in the company's recovery prospects following a 16% stock decline over the past year. The article notes that insider purchases typically predict higher share prices within 30 days and suggest management believes in the company's long-term growth, particularly after deciding to retain its surgical unit rather than divest it.